Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.19 USD | -2.13% | -18.96% | +22.08% |
03-21 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
03-19 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
Evolution of the average Target Price on Adverum Biotechnologies, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Adverum Biotechnologies, Inc.
RBC Capital Markets | |
Mizuho Securities | |
Chardan Research | |
Ladenburg Thalmann | |
Truist Securities | |
SVB Leerink | |
Cantor Fitzgerald | |
Chardan | |
Goldman Sachs | |
UBS |
EPS Revisions
- Stock Market
- Equities
- ADVM Stock
- Consensus Adverum Biotechnologies, Inc.